Kornitzer Capital Management Inc. KS Lowers Stake in Establishment Labs Holdings Inc. $ESTA

Kornitzer Capital Management Inc. KS cut its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 27.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 177,480 shares of the company’s stock after selling 68,605 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Establishment Labs were worth $7,275,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Osaic Holdings Inc. boosted its position in Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares in the last quarter. CWM LLC raised its stake in shares of Establishment Labs by 45.9% during the 2nd quarter. CWM LLC now owns 2,182 shares of the company’s stock worth $93,000 after buying an additional 686 shares during the period. Brian Low Financial Group LLC purchased a new position in shares of Establishment Labs during the 3rd quarter valued at approximately $223,000. Patriot Financial Group Insurance Agency LLC grew its stake in Establishment Labs by 5.2% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,025 shares of the company’s stock valued at $257,000 after acquiring an additional 300 shares during the period. Finally, ARS Investment Partners LLC purchased a new stake in Establishment Labs in the 2nd quarter worth $278,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Stock Down 0.2%

Shares of NASDAQ ESTA opened at $64.95 on Wednesday. The stock has a market cap of $1.89 billion, a PE ratio of -22.87 and a beta of 0.92. The company has a current ratio of 3.33, a quick ratio of 2.10 and a debt-to-equity ratio of 15.06. Establishment Labs Holdings Inc. has a 12-month low of $26.56 and a 12-month high of $78.24. The company has a 50-day moving average of $69.93 and a 200 day moving average of $53.45.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Wednesday, November 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.16. The business had revenue of $53.78 million for the quarter, compared to analysts’ expectations of $52.28 million. Establishment Labs had a negative return on equity of 235.45% and a negative net margin of 43.45%.The business’s revenue for the quarter was up 33.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.59) EPS. As a group, sell-side analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on ESTA shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, December 29th. JPMorgan Chase & Co. raised their price target on shares of Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Wall Street Zen upgraded Establishment Labs from a “sell” rating to a “hold” rating in a report on Sunday, October 19th. Citigroup increased their target price on Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Finally, BTIG Research raised their target price on Establishment Labs from $81.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, December 31st. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $78.86.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.